Specify a stock or a cryptocurrency in the search bar to get a summary
Geron Corporation
0IV3Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. Address: 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
Analytics
WallStreet Target Price
7.36 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 0IV3
Dividend Analytics 0IV3
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0IV3
Stock Valuation 0IV3
Financials 0IV3
Results | 2019 | Dynamics |